The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era

Acta Haematologica

Volumn 130, Issue 4, 2013, Pages 242-246

  Aoki, Kazunari ^a   Tabata, Sumie ^a   Yonetani, Noboru ^a   Matsushita, Akiko ^a   Ishikawa, Takayuki ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Diffuse large B cell lymphoma; Lymphocyte; Monocyte; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE SULFATE;

ABSOLUTE LYMPHOCYTE COUNT; ABSOLUTE MONOCYTE COUNT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84880182299     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000350484     Document Type: Article

References (14)

1. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M: Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lympho-ma in the rituximab era. J Clin Oncol 2010; 28: 2373-2380.
2. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Gold-schmidt N, Chiorazzi M, Staudt LM: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-2169.
3. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohl-man B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM: Stro-mal gene signatures in large-B-cell lympho-mas. N Engl J Med 2008; 359:2313-2323.
4. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L: The absolute mono-cyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011; 25:1502-1509.
5. Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M: Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res 2007; 31:751-757.
6. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-174.
7. Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, Kwon ED, Novak AJ, Markovic SN, Pittelkow MR, Witzig TE, An-sell SM: B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009; 114:2149-2158.
8. Shivakumar L, Ansell S: Targeting B-lympho-cyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematolog-ic malignancies. Clin Lymphoma Myeloma 2006; 7:106-108.
9. Weiner GJ: Rituximab: mechanism of action. Semin Hematol 2010; 47:115-123.
10. Jardin F, Jais JP, Molina TJ, Parmentier F, Pic-quenot JM, Ruminy P, Tilly H, Bastard C, Salles GA, Feugier P, Thieblemont C, Gissel-brecht C, de Reynies A, Coiffier B, Haioun C, Leroy K: Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood 2010; 116:1092-1104.
11. Montes-Moreno S, Martinez N, Sanchez-Es-piridion B, Diaz Uriarte R, Rodriguez ME, Saez A, Montalban C, Gomez G, Pisano DG, Garcia JF, Conde E, Gonzalez-Barca E, Lopez A, Mollejo M, Grande C, Martinez MA, Dun-phy C, Hsi ED, Rocque GB, Chang J, Go RS, Visco C, Xu-Monette Z, Young KH, Piris MA: miRNA expression in diffuse large B-cell lym-phoma treated with chemoimmunotherapy. Blood 2011; 118:1034-1040.
12. Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, Vera P, Copie-Bergman C, Rahmou-ni A, Tilly H, Meignan M, Haioun C: Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lym-phoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 2012; 30:184-190.
13. Song MK, Chung JS, Seol YM, Kim SG, Shin HJ, Choi YJ, Cho GJ, Shin DH: Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010; 21:140-144.
14. Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK: Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007; 21:2227-2230.